Physician profile
Michael D Pavy
NPI 1568405371
$3,189.50
in general payments reported to CMS, 2019-2025
44 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $104 · 2021: $91.75 · 2022: $158 · 2023: $572 · 2024: $770 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $431.45 | 2019-2025 | |
| Celgene Corporation | $253.21 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Janssen Biotech, INC. | $180.12 | 2024-2025 | Tecvayli, Erleada, Rybrevant |
| Merck Sharp & Dohme LLC | $178.20 | 2019-2025 | Keytruda |
| Pfizer INC. | $140.57 | 2023-2025 | |
| Incyte Corporation | $139.13 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Astrazeneca Pharmaceuticals Lp | $133.80 | 2019-2025 | Lynparza, Calquence |
| Glaxosmithkline, LLC. | $113.90 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $113.34 | 2019-2025 | Opdualag, Opdivo |
| Gilead Sciences, INC. | $112.45 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $104.97 | 2019-2025 | Phesgo, Tecentriq, Tecentriq Hybreza |
| Intuitive Surgical, INC. | $101.55 | 2025 | |
| Astellas Pharma US INC | $94.17 | 2020-2025 | Vyloy |
| Amgen INC. | $81.12 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Karyopharm Therapeutics INC. | $71.09 | 2020-2025 | Xpovio |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $69.04 | 2024-2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $62.10 | 2022-2025 | Clonoseq |
| Daiichi Sankyo INC. | $54.29 | 2024-2025 | Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $54.25 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.22 | 2024-2025 | Alunbrig, Ninlaro |
| Jazz Pharmaceuticals INC. | $50.08 | 2019-2025 | |
| Lilly USA, LLC | $49.33 | 2020-2024 | Jaypirca, Retevmo, Verzenio |
| Eisai INC. | $41.92 | 2019-2025 | |
| Exelixis INC. | $37.10 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $34.68 | 2019-2023 | Imbruvica |
| Seagen INC. | $34.65 | 2023 | Tukysa |
| Rigel Pharmaceuticals, INC. | $33.49 | 2021-2025 | Tavalisse, Rezlidhia, Gavreto |
| Beone Medicines USA, INC. | $33.13 | 2025 | Brukinsa |
| Legend Biotech USA INC. | $32.63 | 2025 | Carvykti |
| Taiho Oncology, INC. | $25.76 | 2024 | |
| Genzyme Corporation | $24.56 | 2025 | |
| Deciphera Pharmaceuticals INC. | $23.51 | 2024 | Qinlock |
| Ipsen Biopharmaceuticals, INC | $22.75 | 2023 | Tazverik |
| Mirati Therapeutics, INC. | $21.73 | 2023 | Krazati |
| Geron Corporation | $21.50 | 2024 | Rytelo |
| Stemline Therapeutics INC. | $21.19 | 2023 | Orserdu |
| Springworks Therapeutics, INC. | $19.23 | 2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $19.01 | 2025 | Besremi |
| Kite Pharma, INC. | $18.19 | 2025 | Yescarta |
| Puma Biotechnology, INC. | $18.00 | 2024 | |
| Array Biopharma INC | $17.24 | 2025 | Lorbrena, Braftovi, Mektovi |
| Servier Pharmaceuticals LLC | $16.10 | 2024 | |
| G1 Therapeutics, INC. | $15.46 | 2023 | Cosela |
| Regeneron Healthcare Solutions, INC. | $15.29 | 2023 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.